Measurable or non-measurable disease per RECIST version (v)1.1
Measurable disease according to RECIST criteria (Version 1.1)
Has measurable disease assessed by the investigator based on RECIST version 1.1.
Subjects must have at least one measurable target lesion according to RECIST version (v)1.1
At least 1 measurable target lesion according to RECIST version 1.1. CNS-only measurable disease as defined by RECIST version 1.1 is allowed.
Patient must have at least one measurable site of disease as defined by RECIST version (v)1.1, determined by investigator review
Measurable disease according to RECIST Version 1.1
Must have at least 1 site of measurable disease by RECIST criteria, by version 1.1
Measurable disease according to RECIST version (v)1.1 and obtained by imaging within 28 days prior to registration for protocol therapy; NOTE: A subject with prior brain metastasis may be considered if they comply with inclusion criteria below
Patients with at least one baseline measurable lesion according to RECIST criteria version 1.1.
Measurable disease per RECIST version (v)1.1.
Presence of measurable disease as defined by RECIST version 1.1 Cohort 4: Patient Population: Relapsed/Refractory Ovarian Cancer
Presence of measurable disease as defined by RECIST version 1.1
Measurable disease as per RECIST, version 1.1.
Measurable disease per RECIST version (v)1.1
Patients must have measurable disease as per RECIST (version 1.1)
Patients must have measurable disease by RECIST criteria version 1.1
For Part 1, cohorts 1-3: evaluable disease (per RECIST version 1.1). For Part 1, cohorts 4-6 and Parts 2 and 3: measurable disease (per RECIST version 1.1)
Have measurable disease per RECIST version 1.1.
Have measurable disease, as defined by RECIST version 1.1;
Measurable disease per RECIST version 1.1.
Has measurable disease based on RECIST version1.1
Subjects must have measurable disease according to RECIST (version 1.1)
Histologically-confirmed carcinoma of the breast (either the primary or metastatic lesions) for whom single-agent cytotoxic chemotherapy is indicated. Patients may have either measurable or non-measurable disease according to RECIST version 1.1.
Have measurable disease per RECIST version (v)1.1
Have measurable disease as per RECIST version 1.1; at least 1 of the tumor sites must be amenable to biopsy and this may not be the site of disease used to measure antitumor response
Participants must have at least 2 lesions with measurable disease as defined by RECIST Version 1.1
Participants must have measurable disease by RECIST version 1.1
Has at least one measurable lesion per RECIST version 1.1.
At least one measurable lesion based on RECIST version 1.1
FULL STUDY INCLUSION CRITERIA: Patients must have at least 1 measurable lesion according to RECIST version (v) 1.1
Measurable disease as defined by RECIST criteria (version 1.1)
Measurable target tumors using standard imaging techniques (RECIST version [v.] 1.1 criteria)
Patients must have disease that is measurable by RECIST version 1.1
Patient must have measurable disease as per RECIST version 1.1; at least 1 of the tumor sites must be amenable to biopsy and this may not be the site of disease used to measure antitumor response
Measurable disease as defined by RECIST version 1.1 by radiologic methods on or after the most recent line of therapy. For Cohort 2, imaging must be available for central review.
Measurable disease (revised RECIST; Version 1.1)
Measurable disease (revised RECIST; Version 1.1)
For Part 2, measurable disease as defined by RECIST, Version 1.1 including bone-only disease
For dose-escalation cohort, patient has at least 1 measurable disease as defined by RECIST criteria (Version 1.1). For dose-expansion cohort, patient has at least 1 measurable disease as defined by RECIST criteria (version 1.1) with a lesion larger than 1.5 cm that can be biopsied by core needle biopsy.
Measurable disease according to RECIST Version 1.1
At least one measurable site of disease in the liver according to RECIST version 1.1 and mRECIST criteria
COHORT EXPANSION PHASE: Patient must have measurable lesions as defined by RECIST version 1.1 criteria
Measurable disease as defined by RECIST version 1.1
Measurable disease, as defined by RECIST Version 1.1 (v1.1).
Measurable disease according to RECIST version 1.1.
Disease must be measurable with at least 1 uni-dimensional measurable lesion by RECIST Version 1.1 (including skin lesions)
Subjects must have measurable disease as defined per RECIST Version 1.1.
Demonstrated progression of disease by radiological or clinical assessment (Measurable disease according to RECIST Version 1.1 is NOT required for enrollment)
Subjects must have at least 1 measurable lesion based on RECIST version 1.1.
Measurable disease defined by RECIST version 1.1, or bone-only disease
Patients must have at least one measurable site of disease (according to RECIST [version 1.1] criteria)
Patients must have at least one measurable site of disease according to RECIST version 1.1 criteria
Measurable disease in accordance with RECIST version 1.1
At least 1 target lesion that is measurable by RECIST, Version 1.1
At least 1 target lesion that is measurable by RECIST, Version 1.1
Measurable disease according to the RECIST criteria (version 1.1), for the evaluation of measurable disease
Patient has measurable disease, as determined by the Investigator using RECIST, version 1.1, as determined within 28 days before baseline (C1D1).
Subject must have at least 1 unidimensional measurable NSCLC lesion on a CT scan as defined by RECIST (version 1.1).
Measurable disease, as defined by RECIST version 1.1
Presence of at least 1 measurable lesion according to RECIST version 1.1
PART B: Patients must have measurable disease as per RECIST version 1.1
Measurable disease according to modified RECIST version 1.1
Have evidence of measurable disease as defined by RECIST Version 1.1
Measurable disease according to RECIST version 1.1
Measurable disease by RECIST version 1.1
Subjects must have evidence of measurable disease per RECIST version 1.1 by radiographic techniques or magnetic resonance imaging
Measurable disease by RECIST version 1.1.
Tumors must have measurable disease as per RECIST (version 1.1);
At least one measurable lesion by CT scan or MRI based on RECIST version 1.1
Patient must have measurable lesions as defined by RECIST version 1.1 criteria
Measurable disease according to RECIST criteria (Version 1.1)
Patients must have measurable disease per RECIST criteria version (v.) 1.1
At least one lesion measurable by RECIST Version 1.1.
At least 1 unresectable lesion on a CT (Computerized Tomography) scan that is measurable as defined by RECIST, Version 1.1
Measurable disease (i.e., present with at least one measurable lesion per RECIST, version 1.1).
Measurable disease as per RECIST Version 1.1 criteria.
Measurable disease using RECIST criteria (version 1.1).
Measurable disease per RECIST version 1.1 (Arm A and B) and modified RECIST for Arm C.
Measurable disease at baseline in accordance with RECIST Version 1.1
Measurable disease as per RECIST guideline (Version 1.1);
Patients with measurable or non-measurable disease as determined by modified RECIST version 1.0 in dose-escalation phase, and patients with at least one measurable lesion as determined by RECIST 1.0 in expansion phase.
Measurable disease according to RECIST version 1.1.
Measurable disease at baseline as per RECIST version 1.1
Has at least one measurable lesion per RECIST version 1.1
Subjects must have measurable disease by RECIST Version 1.1.
Radiographic evidence of unidimensionally measurable disease; lesions will be considered measurable or non-measurable as per definitions provided in RECIST version 1.1
Histologically confirmed, metastatic TNBC with measurable disease per RECIST version 1.1.
Measurable disease per RECIST version 1.1.
